| Literature DB >> 24083352 |
Ioanna D Pavlopoulou1, Koralia A Michail, Evangelia Samoli, George Tsiftis, Konstantinos Tsoumakas.
Abstract
BACKGROUND: In Greece, several new childhood vaccines were introduced recently but were reimbursed gradually and at different time points. The aim of this study was to assess immunization coverage and identify factors influencing complete and age-appropriate vaccination among children attending public nurseries in the municipal district of Athens.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24083352 PMCID: PMC3850659 DOI: 10.1186/1471-2458-13-908
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Definitions of complete and age- appropriate vaccination
| DTP/DTaP | 3 doses by the age of 12 months, or | 3 doses | 4 doses | 5 doses |
| 4 doses by the age of 24 months, or | ||||
| 5 doses by the age of 60 months | ||||
| OPV/IPV | 2 or 3 doses by the age of 12 months plus 1 dose ≥ 12 months, or | 3 doses | 3 or 4 doses | 4 or 5 doses |
| 3 doses by the age of 24 months or | ||||
| 4 or 5 doses by the age of 60 months | ||||
| Hib | 2 or 3 doses by the age of 12 months plus | 2 or 3 doses | ≥ 3 doses | ≥ 3 doses |
| 1 dose between ≥ 12 – 23 months, or | ||||
| 2 doses between 12 – 24 months, or | ||||
| 1 dose at the age of ≥ 24 months. | ||||
| MMR | 1 dose between ≥ 12 < 48 months, or | - | ≥ 1 dose | 2 doses |
| 2 doses between ≥ 48 – 60 months | ||||
| HBV | ≥ 3 doses | 3 doses | 3 doses | 3 doses |
| Men C | 2 doses < 12 months, or | 2 or 3 doses | ≥ 3 doses | ≥ 3 doses |
| 1 dose ≥ 12 months | ||||
| PCV7 | 3 doses by the age of 12 months, plus | 3 doses | 4 doses | 4 doses |
| 1 dose ≥ 12 – 23 months, or | ||||
| 2 doses from the age of 7 – 12 months, plus | ||||
| 1 dose ≥ 12 – 23 months, or | ||||
| 2 doses between 12 – 23 months, or | ||||
| 1 dose ≥ 24 months | ||||
| Var | 1 dose between ≥ 12 < 48 months, or | - | ≥ 1 dose | 2 doses |
| 2 doses between ≥ 48 – 60 months | ||||
| HAV | ≥ 2 doses at ≥ 12 months | - | 2 doses | 2 doses |
DTP/DTaP: diphtheria, tetanus, pertussis/ acellular pertussis vaccine; OPV/IPV: live attenuated/inactivated polio vaccine; HBV: hepatitis B vaccine; MMR: measles, mumps, rubella vaccine; Hib: haemophilus influenzae type b vaccine; Men C: conjugated meningococcal C vaccine; PCV7: conjugated pneumococcal 7-valent vaccine; Var: varicella vaccine; HAV: hepatitis A vaccine.
Selected demographic characteristics of the sample
| | |
| Male | 368 (51.7) |
| Female | 363 (48.3) |
| | |
| ≤ 24 | 27 (3.7) |
| 25 - 48 | 363 (50.3) |
| 49 - 65 | 341 (45.9) |
| | |
| Greek | 504 (68.9) |
| Albanian | 126 (17.2) |
| Other immigrant | 101 (13.8) |
| | |
| 1 | 183 (14.7) |
| 2 | 417 (57.4) |
| ≥ 3 | 131 (17.9) |
| | |
| IKA | 452 (61.1) |
| Other | 279 (38.9) |
| | |
| High school or less | 433 (59) |
| College/University | 297 (41.1) |
IKA: Social Security Institute; * One mother deceased.
Parental attitudes towards vaccines
| | |
| Protection, immunity, good health | 354 (47.9) |
| Prevention of infections | 162 (22.6) |
| Pediatrician’s advice | 103 (14.4) |
| It is compulsory | 112 (15.1) |
| | |
| Yes | 75 (10.3) |
| Probably yes | 21 (2.9) |
| Maybe | 118 (15.9) |
| Probably not | 56 (7.7) |
| No | 461 (63.3) |
| | |
| Yes | 487 (66.4) |
| No | 244 (33.6) |
| | |
| Private pediatrician* | 239 (33.4) |
| Insurance doctor or clinic† | 485 (65.7) |
| Public health clinic† | 7 (0.9) |
* Doctor’s fee only, †No additional costs.
Number and weighted proportions for age- appropriate and complete immunization of the study population
| | ||||
|---|---|---|---|---|
| DTP/DTaP | 696 (95.4) | 594 (84.8) | 19 (33.7) | 688 (94,2) |
| OPV /IPV | 629 (86.8) | 602 (86.2) | 22 (38.8) | 723 (98.9) |
| Hib | 688 (94.2) | 559 (80.0) | 37 (65.6) | 691 (94.5) |
| MMR | - | 660 (90.5) | 20 (35.9) | 462 (63.7) |
| HBV | 202 (27.7) | 605 (86.1) | 55 (97.4) | 688 (94.3) |
| MenC | 164 (22.9) | 111 (16.1) | 7 (12.4) | 671 (91.9) |
| PCV7 | 113 (16.0) | 66 (9.8) | 2 (4.0) | 537 (73.1) |
| Var | - | 430 (60.4) | 17 (30.1) | 435 (61.1) |
| HAV | - | 6 (0.9) | 41 (71.7) | 450 (62.0) |
| All 5 traditional vaccines* (DTP/DTaP, OPV/ IPV, Hib, MMR, HBV) | 163 (22.6) | 417 (60.1) | 4 (6.8) | 414 (56.9) |
| All 3 new* (PCV7, Var, MenC) | 62 (8.8) | 35 (5.2) | 1 (2.0) | 327 (44.2) |
DTP/DTaP: diphtheria, tetanus, pertussis/ acellular pertussis vaccine; OPV/IPV: live attenuated/inactivated polio vaccine; HBV: hepatitis B vaccine; MMR: measles, mumps, rubella vaccine; Hib: haemophilus influenzae type b vaccine; Men C: conjugated meningococcal C vaccine; PCV7: conjugated pneumococcal 7-valent vaccine; Var: varicella vaccine; HAV: hepatitis A vaccine.
* For age-appropriate vaccination at 12 months, the MMR vaccine is excluded from the traditional vaccines denominator and the HAV is excluded from the new vaccines.
Multiple logistic regression derived odds ratios (and 95% Confidence Intervals) for the association between sample characteristics and immunization with all 5 traditional vaccines (DTP/DTaP, OPV/IPV, MMR, Hib, HBV)
| | ||||||
|---|---|---|---|---|---|---|
| 0.37 (0.30-0.45) | <0.001 | 0.83 (0.68-1.01) | 0.058 | 0.85 (0.69-1.05) | 0.850 | |
| Other | Reference | |||||
| Greek | 1.56 (1.04-2.36) | 0.034 | 0.98 (0.61-1.59) | 0.930 | 2.57 (1.71-3.87) | <0.001 |
| 1 | Reference | |||||
| 2 | 1.02 (0.69-1.50) | 0.932 | 1.64 (1.03-2.62) | 0.038 | 0.95 (0.63-1.42) | 0.796 |
| 3+ | 0.79 (0.48-1.32) | 0.378 | 1.49 (0.83-2.69) | 0.181 | 0.63 (0.37-1.06) | 0.627 |
| ≤12 years | Reference | |||||
| >13 years | 0.84 (0.59-1.18) | 0.308 | 0.99 (0.68-1.46) | 0.977 | 0.88 (0.61-1.27) | 0.880 |
| ≤ 4-valent | Reference | |||||
| 5- or 6-valent | 1.30 (0.92-1.83) | 0.138 | 3.00 (1.91-4.72) | <0.001 | 3.19 (2.26-4.51) | <0.001 |
| No | Reference | |||||
| Yes | 0.88 (0.49-1.58) | 0.657 | 0.85 (0.43-1.70) | 0.651 | 0.51 (0.28-0.92) | 0.025 |
| No | Reference | |||||
| Yes | 0.94 (0.64-1.37) | 0.741 | 1.06 (0.70-1.60) | 0.800 | 0.99 (0.67-1.45) | 0.949 |
| Privately | Reference | |||||
| Insurance clinic / Public health clinic | 1.17 (0.78-1.76) | 0.440 | 0.97 (0.61-1.55) | 0.907 | 0.88 (0.58-1.33) | 0.543 |
| IKA | Reference | |||||
| Other | 0.97 (0.63-1.48) | 0.876 | 1.39 (0.87-2.22) | 0.165 | 1.26 (0.82-1.94) | 0.296 |
DTP/DTaP: diphtheria, tetanus, pertussis/ acellular pertussis vaccine; OPV/IPV: live attenuated/inactivated polio vaccine; HBV: hepatitis B vaccine; MMR: measles, mumps, rubella vaccine; Hib: haemophilus influenzae type b vaccine.
IKA: Social Security Institute.
Multiple logistic regression derived odds ratios (and 95% Confidence Intervals) for the association between sample characteristics and immunization with all 3 newer vaccines (MenC, PCV7, Var)
| | ||||||
|---|---|---|---|---|---|---|
| 0.77 (0.65-0.91) | 0.002 | 0.47 (0.35-0.64) | <0.001 | 0.45 (0.29-0.71) | 0.001 | |
| Other | Reference | |||||
| Greek | 1.29 (0.88-1.90) | 0.188 | 2.10(0.91-4.86) | 0.082 | 2.95 (0.91-9.50) | 0.071 |
| 1 | Reference | |||||
| 2 | 0.91 (0.64-1.31) | 0.621 | 0.58 (0.31-1.09) | 0.092 | 0.41 (0.19-0.90) | 0.026 |
| 3+ | 0.77 (0.48-1.22) | 0.265 | 0.42 (0.18-1.01) | 0.053 | 0.27 (0.08-0.89) | 0.031 |
| ≤12 years | Reference | |||||
| >13 years | 0.73 (0.53-1.02) | 0.061 | 0.68 (0.38-1.22) | 0.198 | 0.42 (0.19-0.94) | 0.035 |
| ≤ 4-valent | Reference | |||||
| 5- or 6-valent | 1.09 (0.78-1.50) | 0.630 | 3.46 (1.51-7.92) | 0.003 | 2.24 (0.88-5.68) | 0.090 |
| No | Reference | |||||
| Yes | 0.95 (0.67-1.34) | 0.764 | 1.22 (0.65-2.28) | 0.538 | 1.28 (0.57-2.90) | 0.551 |
| Privately | Reference | |||||
| Insurance clinic / Public health clinic | 1.39 (0.95-2.03) | 0.086 | 0.64 (0.32-1.30) | 0.216 | 0.56 (0.23-1.36) | 0.199 |
| IKA | Reference | |||||
| Other | 1.13 (0.77-1.66) | 0.545 | 1.67 (0.84-3.34) | 0.144 | 1.69 (0.70-4.11) | 0.244 |
Men C: conjugated meningococcal C vaccine; PCV7: conjugated pneumococcal 7-valent vaccine; Var: varicella vaccine.
IKA: Social Security Institute.